CAR-T Immunotherapy Improvement. A Novel Approach and the Firm Behind It

Nonstop Improvements and Nonstop Discoveries
In CAR-T Immunotherapy
As we said in the article about checkpoint inhibition as cancer immunotherapy, the approaches that aim at enabling the immune system to fight cancer cells were created to stay and improve and become the gold standard for cancer treatment. Chimeric antigen receptor T cell (CAR-T) therapeutics are speeding their way towards approval in 2017. The two products expected to reach the market this year come from Novartis (NVS) and Kite (KITE). Recently, the . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.